genzyme
Still No Deal Between Sanofi-Aventis and Genzyme
12:45PM 2/11/2011
What is preventing the French pharmaceutical group and U.S. biotech from reaching a merger agreement?
Genzyme Tries to Convince Sanofi-Aventis Its MS Drug Is Worth More
10:50AM 12/20/2010
Company News, Genzyme Corporation , Sanofi Aventis, Stocks in the News
The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a battle that has now gone on for five months.
Genzyme Rejects Sanofi-Aventis Takeover Bid
7:30PM 10/22/2010
Company News, Technology, Health Care, Genzyme Corporation , Sanofi Aventis
Genzyme, which makes drugs to treat leukemia and multiple sclerosis, has rejected a hostile takeover bid from French drugmaker Sanofi-Aventis. The offer "dramatically undervalues" Genzyme, the company said Friday, putting its value about 30% higher.
Sanofi Says MS Drug Reduces Relapses
12:20PM 10/15/2010
Company News, Health Care, Genzyme Corporation , Sanofi Aventis, Stocks in the News
French pharmaceutical giant Sanofi-Aventis says its multiple sclerosis drug teriflunomide significantly cut relapses in patients who took the once-daily oral treatment.
Sanofi Denies Offering $69-$80 Price Range to Genzyme
8:30AM 10/08/2010
Company News, Health Care, Genzyme Corporation , Johnson & Johnson, Pfizer, Sanofi Aventis, Stocks in the News
There's a new plot twist in the takeover battle between French pharmaceutical giant Sanofi-Aventis and U.S. drugmaker Genzyme. A regulatory filing made by Genzyme on Thursday claims Sanofi may be willing to go much higher than its current $69 bid -- a claim the French company disputes.
Sanofi-Aventis Launches Hostile Bid for Genzyme
6:55AM 10/04/2010
After months of courting U.S. drugmaker Genzyme, French pharmaceutical company Sanofi-Aventis launched a hostile bid valued at approximately $18.5 billion, or $69 a share, for all outstanding shares of Genzyme common stock.
Sanofi Is in No Rush to Reach Deal With Genzyme
9:34AM 9/15/2010
Company News, Health Care, Genzyme Corporation , Sanofi Aventis, Stocks in the News
Sanofi-Aventis CEO Chris Viehbacher said Wednesday that he believes his French pharmaceutical company will eventually buy U.S. biotech company Genzyme at a reasonable price. However, he expects it will take some time to agree on a deal, and he won't rush into anything.
Genzyme Sells Genetic Testing Unit to LabCorp for $925 Million
6:59AM 9/13/2010
Investing, Genzyme Corporation , Sanofi Aventis, Stocks in the News
Genzyme (GENZ) announced that it has agreed to sell Genzyme Genetics to Laboratory Corporation of America Holdings (LabCorp) (LH) for for $925 million in cash.
Cambridge, Mass.-based Genzyme said that under the terms of the agreement, LabCorp will purchase the genetic testing business in its...
Sanofi-Avenits Won't Bid More Than $70 a Share for Genzyme
2:49PM 8/25/2010
Company News, Health Care, Genzyme Corporation , Johnson & Johnson, Sanofi Aventis, GlaxoSmithKline, Stocks in the News
Pharmaceutical giant Sanofi-Aventis is unwilling to pay more than $70 a share in its bid to buy biotech firm Genzyme, media outlets reported Wednesday. If a deal can't be reached, the French drugmaker may consider alternative takeover targets.
More Stories
Next Page →Market Movers
| Symbol | Last | Change / % | Volume |
|---|
Most Actives
| 8.09 | -0.10 -1.16% | 144.54M | |
| 2.19 | +0.25 +12.63% | 92.86M | |
| 29.64 | -2.35 -7.35% | 23.01M | |
| 18.82 | -0.32 -1.65% | 22.24M |
% Gainers
| 32.67 | +8.77 +36.69% | 11.64M | |
| 89.23 | +12.84 +16.81% | 7.21M | |
| 2.19 | +0.25 +12.63% | 92.86M | |
| 10.56 | +1.16 +12.34% | 2.63M |
% Losers
DailyFinance Wire
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
Newswire
- Bernanke: Weak housing has hurt consumer...
- Turbo-traders take Bank of America for a ride
- Greece caught between protests, austerity...
- Stocks fall sharply as Greek deal is held up
- Trade deficit widens to $48.8 billion in...
- Feds investigate door fires in 2007 Camrys,...
- NYSE Euronext profit down on blocked merger...
- Obama call for manufacturing revival a tough...
- Petrobras Shares Volatile on $225 Billion Development Plan (PBR)
- Morning Movers (CIE, ALU, LNKD, AMRS, XIDE)
- AEP Dividend Growth Still Looks Safe Ahead (AEP)
- Arch Coal Tumbles on Earnings, Forecast (ACI, ANR, PCX, BTU, CNX)
- 2011 Trade Deficit Hits 3-Year High, Over $550 Billion
- Today’s Best Market Rumors (2/10/2012) Apple iPad, Google Entertainment
- Top Analyst Upgrades & Downgrades (ALTR, AMSC, BIIB, CELG, COH, CSTR, COP, FSLR, GILD, HAIN, MA, RF, TRLG)
- Morning Wire — US Stock-Index Futures Down Sharply
Follow Us
